Uppsala, February 17, 2023. Today the pharmaceutical company Dicot presented the latest study of the mechanism of action of LIB-01 at the European Society for Sexual Medicine's annual congress in Rotterdam. The study shows that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors, and that LIB-01 may thus represent a completely new generation of potency drugs.
The European Society for Sexual Medicine (ESSM) is a leading scientific organization in sexual medicine. The annual congress is now underway, bringing together prominent researchers and doctors in the field from all over the world. Today, Dicot's latest study of the mechanism of action of LIB-01 was presented, that is, how the drug affects underlying processes so that the desired effect occurs.
Dicot has previously announced the results of the ex vivo study, which show that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors such as Viagra, and that LIB-01 may thus represent a completely new generation of potency drugs. The study results were selected by ESSM's scientific council to be presented at the annual congress in 2023.
"ESSM is well attended this year and a fantastic opportunity for us to present study results for LIB-01. It is clear that there is a great interest in our study results among doctors and researchers within the field ", says Elin Trampe, CEO of Dicot.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.